Literature DB >> 12417015

Protein kinase C beta (PKC beta): normal functions and diseases.

Toshiaki Kawakami1, Yuko Kawakami, Jiro Kitaura.   

Abstract

PKC beta I and PKC beta II are DAG- and Ca(2+)-dependent conventional or classical isoforms of protein kinase C. Generated by alternative splicing from a single gene, they differ at their C-terminal 50 (beta I) or 52 (beta II) residues. They are expressed as major PKC isoforms in a variety of tissues, and thus the functions ascribed to "PKC" based on early studies using phorbol esters and PKC inhibitors could be attributed to them. As tools to probe into isoform-specific functions have recently become available, our understanding of the normal functions of these isoforms has dramatically increased. This minireview will focus mainly on two areas of signal transduction where the roles of PKC beta I and PKC beta II are relatively well-characterized: immunoreceptor and insulin receptor systems. Their involvement in disorders due to pertubations in these signaling systems, i.e., immunodeficiencies and diabetes, is also reviewed. Finally, patterns of PKC action in these and other biologic systems are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417015     DOI: 10.1093/oxfordjournals.jbchem.a003273

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  24 in total

1.  Differential effects of PKA-controlled CaMKK2 variants on neuronal differentiation.

Authors:  Wenguang Cao; Muhammad Sohail; Guodong Liu; Geremy A Koumbadinga; Vincent G Lobo; Jiuyong Xie
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

Review 2.  Protein kinase C isozymes as regulators of sensitivity to and self-administration of drugs of abuse-studies with genetically modified mice.

Authors:  Michael Foster Olive; Philip M Newton
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

3.  Extraction and validation of substructure profiles for enriching compound libraries.

Authors:  Wee Kiang Yeo; Mei Lin Go; Shahul Nilar
Journal:  J Comput Aided Mol Des       Date:  2012-09-16       Impact factor: 3.686

4.  Carnitine revisited: potential use as adjunctive treatment in diabetes.

Authors:  R A Power; M W Hulver; J Y Zhang; J Dubois; R M Marchand; O Ilkayeva; D M Muoio; R L Mynatt
Journal:  Diabetologia       Date:  2007-02-20       Impact factor: 10.122

5.  Priming of eosinophils by GM-CSF is mediated by protein kinase CbetaII-phosphorylated L-plastin.

Authors:  Konrad Pazdrak; Travis W Young; Christof Straub; Susan Stafford; Alexander Kurosky
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

6.  PKCβ/NF-κB pathway in diabetic atrial remodeling.

Authors:  Haili Wang; Yuanyuan Xu; Aiqing Xu; Xinghua Wang; Lijun Cheng; Sharen Lee; Gary Tse; Guangping Li; Tong Liu; Huaying Fu
Journal:  J Physiol Biochem       Date:  2020-10-21       Impact factor: 4.158

7.  A Ras activation pathway dependent on Syk phosphorylation of protein kinase C.

Authors:  Yuko Kawakami; Jiro Kitaura; Libo Yao; Robert W McHenry; Yu Kawakami; Alexandra C Newton; Shin Kang; Roberta M Kato; Michael Leitges; David J Rawlings; Toshiaki Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-24       Impact factor: 11.205

Review 8.  Alternative splicing in the NF-kappaB signaling pathway.

Authors:  Joshua R Leeman; Thomas D Gilmore
Journal:  Gene       Date:  2008-07-22       Impact factor: 3.688

9.  Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-β isoform in the endothelium.

Authors:  Qian Li; Kyoungmin Park; Chenzhong Li; Christian Rask-Madsen; Akira Mima; Weier Qi; Koji Mizutani; Paul Huang; George L King
Journal:  Circ Res       Date:  2013-06-11       Impact factor: 17.367

10.  The Potential Use of Peripheral Blood Mononuclear Cells as Biomarkers for Treatment Response and Outcome Prediction in Psychiatry: A Systematic Review.

Authors:  Jobbe Goossens; Manuel Morrens; Violette Coppens
Journal:  Mol Diagn Ther       Date:  2021-05-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.